Anticipated Shortage

SANDOZ AFATINIB

SANDOZ CANADA INCORPORATED

This is a national manufacturer shortage report. It does not confirm whether the product is unavailable at your local pharmacy — call ahead or ask your pharmacist.

Quick answers

Is there a shortage of SANDOZ AFATINIB in Canada?

A shortage of SANDOZ AFATINIB 30MG is expected: the manufacturer reported it to Health Canada as an anticipated shortage (last updated September 14, 2026), but it has not started yet.

Why is SANDOZ AFATINIB not available?

The reason the manufacturer reported: Shortage of an active ingredient.

When will SANDOZ AFATINIB be available again?

The manufacturer's estimated resolution date is November 6, 2026. This is an estimate and can change; follow this page to get an email when the status changes.

Can I still get this?Possibly — same-ingredient product records found

StatusAnticipated Shortage

Same-ingredient products on file2 products

Expected resolution~39 days remaining (estimate)

Affected strength30MG

Last updated2026-09-14

Other Products Containing the Same Active Ingredient

These are other Health Canada-approved human drug products containing the same active ingredient, not currently reported in shortage. Strength, dosage form, and route can still differ — ask your pharmacist whether any of these are appropriate for you. This isn't a guarantee of current stock.

Closest Matches

TEVA-AFATINIB

TEVA CANADA LIMITED

30MG · DIN 02514605

Same strengthSame dosage formSame routeNo current shortage

Compare these two →

MAR-AFATINIB

MARCAN PHARMACEUTICALS INC

30MG · DIN 02517027

Same strengthSame dosage formSame routeNo current shortage

Compare these two →

What this means

Does this mean my pharmacy is already out of stock?

No — this shortage hasn't started yet. It's an early warning that supply may become tight, based on information from the manufacturer.

What should I do?

No action is needed yet. It's worth asking your pharmacist at your next refill whether they expect any disruption for this product.

Estimated Resolution

2026-11-06

~39 days remaining (estimate)

This is the manufacturer's estimated date, not a guarantee — actual resolution may come earlier or later.

DIN

02512785

Strength

30MG

Dosage Form

TABLET

Route

ORAL

Active Ingredient

AFATINIB

Tier

Unrated

Last Updated

2026-09-14

Reason for Shortage

Shortage of an active ingredient.

Source

View original report on healthproductshortages.ca ↗

Other Products from SANDOZ CANADA INCORPORATED

Other Health Canada-approved products made by the same manufacturer — not necessarily related to this shortage, and not necessarily in shortage themselves.

ACETYLCYSTEINE SOLUTION

200MG · DIN 02243098

ACLASTA

5MG · DIN 02269198

ALFENTANIL INJECTION USP

500MCG · DIN 02248181

AMIKACIN SULFATE INJECTION USP

250MG · DIN 02242971

AMIODARONE HYDROCHLORIDE FOR INJECTION

50MG · DIN 02242325

AMOXICILLIN SODIUM AND POTASSIUM CLAVULANATE FOR INJECTION

DIN 02495929